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Background: Brain- derived neurotrophic factor (BDNF) is linked to neurodegenerative diseases (e.g. Alzheimer
disease and Parkinson disease) which are often characterized by olfactory impairment. A specific single nucleotide
polymorphism of the BDNF gene, the Val66Met, modulates intracellular trafficking and activity-dependent secretion
of BDNF protein. The aim of this study was to investigate a possible association between brain- derived
neurotrophic factor Val66Met polymorphism and olfactory function, a well-known biomarker for neurodegeneration,
in healthy young adults. A total of 101 subjects (45 males, age 38.7 ± 9.4 years) were assessed using the Sniffin’
Sticks Extended Test, a highly reliable commercial olfactory test composed of three sub-parts, calculating olfactory
threshold (sensitivity), odor discrimination and odor identification. The Val66Met polymorphism was determined by
polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) analysis.
Results: An impaired function in Met carriers was found, especially when compared to subjects with Val/Val genotype,
in the threshold (5.5 ± 2.0 vs 6.5 ± 1.8, p = 0.009), discrimination (10.3± 2.5 vs 11.9 ± 2.2, p = 0.002), and identification
task (13.3 ± 1.6 vs 14.1 ± 1.3, p = 0.007), as well as in the overall TDI Score (29.1 ± 4.5 vs 32.6 ± 3.9, p < 0.001).
Conclusions: These findings appear to have implications for the evaluation of olfactory function and the relation of its
impairment to cognitive decline and neurodegenerative disease.
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Olfactory function is a well-known biomarker for neu-
rodegeneration. The loss of olfaction is, in fact, often asso-
ciated with many neurodegenerative conditions, such as
Parkinson’s (PD) and Alzheimer’s (AD) diseases [1,2]. A
decrease in olfactory function could be an early alarm
warning for such conditions, since its onset occurs prior
to the first clinical signs of pathology by 4–5 years. Many
factors are known to influence olfactory ability, including
genetic variability [3,4]. Moreover, an increasing number
of animal studies, as well as clinical studies, confirm the
important role of the brain- derived neurotrophic factor
(BDNF) in neurodegenerative diseases [5-9]. In particular,
BDNF, a member of the neurotrophin family, plays an im-
portant role in the development and maintenance of
neurons and neuronal connections in the central and per-
ipheral nervous system [10]. A common functional single* Correspondence: aborghini@ifc.cnr.it
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reproduction in any medium, provided the ornucleotide polymorphism of the BDNF gene, the
Val66Met, modulates intracellular trafficking and activity-
dependent secretion of BDNF protein, and impairs the
ability of BDNF to undergo activity-dependent release, but
not general secretion [11-14]. The Val66Met is located at
nucleotide 196 (G/A) in the pro-protein of BDNF and pro-
duces an amino acid substitution, valine to methionine.
The Met allele inhibits the intracellular trafficking and the
regulated secretion of the BDNF protein at synapses [11].
Published data support a role for BDNF gene variant in
some neuropsychiatric disorders. Guerini et al. showed a
correlation between BDNF Val66Met polymorphism and
cognitive impairment in Italian patients with Parkinson’s
disease [15]. BDNF Val66Met is also reported to be associ-
ated with AD and/or schizophrenia, as well as other
psychoses [16,17], but the findings are still contradictory
[18,19]. Furthermore, evidence suggested that BDNF
might be relevant for olfactory processing [20]. In fact,
BDNF induces the proliferation and survival of neuronal
precursor cells/immature neurons in the olfactory system
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system, respectively [20]. A recent work found an associ-
ation between mature BDNF levels and increasing of mi-
tral cell, pyramidal-like neurons, excitability olfactory bulb
level in the mice [21]. Furthermore, an experimental study
showed that BDNF play a pivotal role in the olfactory
neurogenesis, contributing in olfactory epithelium to the
early stage of regeneration and in olfactory bulb in the late
stage of regeneration of olfactory receptor neurons [22].
Additionally, there are experimental studies in animals
linking the genetic variant to olfactory function [23], but,
to date, little is known about this association in humans,
except for a recent population-based study that showed a
link between age-related olfactory decline and BDNF
Val66Met polymorphism in the older age cohort (70–
90 years) [24]. In order to better define the influence of
BDNF Val66Met polymorphism on the olfactory function,
the purpose of this study was to assess a possible associ-
ation between BDNF Val66Met polymorphism and olfac-
tory ability in healthy young adults, population less
subjected to comorbidities possibly associated with an ol-
factory dysfunction if compared with elderly people.Methods
Ethics
The present study was approved by the Ethics Commit-
tee for clinical trials with medicines - Pisa Hospital, Italy,
with protocol number 36169.Study population
A total of 101 volunteers (45 males, age 38.7 ± 9.4 years)
were enrolled for the study. Written informed consent was
obtained from all subjects. The volunteers were chosen
from among young adults, as this population is less subject
to diseases affecting olfactory function. A clinical question-
naire was filled out by the volunteers and collected. Many
exclusion criteria were applied to obtain a clean population,
with absence of pathological conditions possibly affecting
the sense of smell. In particular, subjects having nasal prob-
lems, such as flu, rhinitis, sinusitis, allergies, were excluded
from the analysis, together with subjects having used medi-
cations such as nasal decongestants, antidepressants and
anxiolytics in the 2-month period before administration of
the olfactory test. Familiar history of neurodegeneration
was also considered, and subjects with parents or first de-
gree relatives with conditions such as Alzheimer’s disease,
Parkinson’s disease, Amyotrophic Lateral Sclerosis, Lewy
body disease, Huntington’s chorea or schizophrenia were
excluded from the study. Among normal subjects matching
these criteria, people with normal general cognitive func-
tion evaluated with standardized neuropsychological test
batteries by a professional neuropsychologist were included,while subjects with sub-normal scores were not considered
in the analysis.
Olfactory assessment
Olfactory function was assessed using the Sniffin’ Sticks
Extended Test [25,26], an olfactory test commercially dis-
tributed by Burghart, Medizintechnik, GmbH (Wedel,
Germany). It consists of three different sub-tests, assessing
the olfactory sensitivity (threshold), discrimination and
identification, typical tasks of the olfactory system. In this
version of the test, the olfactory sensitivity to n-butanol
was employed. The olfactory threshold is considered as
the minimum concentration of an odorant (n-butanol)
that can be detected by a subject. N-butanol was pre-
sented in 16 different dilutions in felt tip pens. For each
trial the blindfolded subject was subjected to three differ-
ent stimuli, one consisting of a given concentration of n-
butanol, and the other two with blank stimuli. The subject
was asked which of the three stimuli contained the n-
butanol (or, equivalently, which of the three stimuli was
the strongest). Depending upon the correct and wrong an-
swers given, the concentration of the stimulus was
changed and the trial was repeated up to seven staircase
reversals. The threshold score was calculated by per-
forming a mean of the values of four last reversals. The ol-
factory discrimination’s aim was to assess the subject’s
ability to discriminate between different odorants. Even in
this case the subject was blindfolded and 16 different trip-
lets of odorants were presented. For each triplet, two felt
tip pens contained the same odorant, while the third one
held a different substance. The subject was asked which of
the three pens contained the different odorant. The olfac-
tory identification test aimed to evaluate the subject’s abil-
ity to correctly identify an odorant. The subject was
presented with16 different odorants and asked to identify
them by choosing between four possible odors for each
trial. In this final test, the subject was not blindfolded.
Each of these tests yielded a score, and the total sum of
the three sub-scores was called “TDI (Threshold Discrim-
ination Identification) Score”, relating to olfactory func-
tion. We chose to employ a bilateral testing, in order to
avoid possible false results due to the congestion of one of
the two nostrils, even though the presence of flu and/or
nasal problems was included in the exclusion criteria of
the survey. The test was performed once for each partici-
pant, given the high test-retest reliability of the method
employed (r = 0.80 for Odor Discrimination, r = 0.88 for
Odor Identification, r = 0.92 for Odor Threshold) [25,27].
The reliability data obtained in previous pilot studies are
in agreement with data above mentioned.
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood
leukocytes. The BDNF Val66Met polymorphism was
Table 1 Demographic characteristics of study population
Val/Val n = 60 Met carriers n = 41
Age (mean ± SD) (years) 38.1 ± 8.5 39.7 ± 10.7
Gender, males n (%) 24 (40) 21 (51)
Smoking habit, n (%) 17 (28) 12 (29)
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and restriction enzyme digestion, as previously described
[28]. Briefly, a 274 bp DNA segment including the poly-
morphic site was amplified by PCR using a set of oligo-
nucleotide primers: 5’-AAA GAA GCA AAC ATC CGA
GGACAA G-3’ and 5’-ATT CCT CCA GCA GAA AGA
GAA GAG-3’, sense and antisense primers respectively.
The PCR product was digested with NlaIII restriction
endonuclease, resulting in two fragments of 57 and
217 bp for the G allele and in three fragments of 57, 77,
140 bp for the A allele. The products were separated by
2% agarose gel stained with ethidium bromide. Genotype
results were regularly confirmed by random repetition of
the samples with no discrepancies.Figure 1 Impact of the BDNF Val66Met polymorphism on olfactory ab
(top left), discrimination (top right), identification (bottom left) and the overaStatistical methods
Statistical analysis of the data was performed with the
StatView statistical package, version 5.0.1 (Abacus Con-
cepts, Berkeley, CA, USA). Data are expressed as mean ±
SD. Student’s T-test was used to examine demographic
data and to compare individual’s genotypes with olfactory
tests called “Threshold Test”, “Discrimination Test” and
“Identification Test”, as well as with the overall “TDI
Score”. Fisher’s exact T test was used for post-hoc tests.
The level of significance was set at p < 0.05 for all statis-
tical analyses. Assuming a frequency of 23% for the risk al-
lele, the size of the study population allows to detect a
15% difference or more in olfactory parameters in the het-
erozygous carriers of Met variant the with a power of β =
80% by means of a two-sided t-test with α = 5%.
Results
We investigated a possible association of BDNF
Val66Met polymorphism with olfactory function in a
group of young adults. Due to the low population fre-
quency of the Met/Met genotype (<5%), participants
were divided into two groups, either homozygous for theility. BDNF Val66Met polymorphism and the olfactory threshold
ll TDI Score (bottom right).
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the Met allele (Met/Met, Val/Met), respectively. The
demographic characteristics of the study population are
reported in Table 1. There was no significant difference
in age, gender and smoking habits between groups. The
genotype’s distribution of Val66Met polymorphism ob-
served in both patients and controls satisfied the Hardy-
Weinberg equilibrium and were comparable with that
previously observed in Caucasian subjects [11]. There
was significant evidence for the impact of the BDNF
Val66Met polymorphism on olfactory ability. In particu-
lar, Met carriers showed impaired olfactory function
compared with Val/Val carriers in all three sub-tests, as
well as in the overall TDI Score. The impairment was
marked in all tasks, in the case of Olfactory Threshold
(5.5 ± 2.0 vs 6.5 ± 1.8, p = 0.009), Olfactory Discrimin-
ation (10.3 ± 2.5 vs 11.9 ± 2.2, p = 0.002), and Identifica-
tion (13.3 ± 1.6 vs 14.1 ± 1.3, p = 0.007), as well as in the
TDI Score (29.1 ± 4.5 vs 32.6 ± 3.9, p < 0.001), suggesting
a clear effect of the Val/Met variant on olfactory func-
tion, as displayed in Figure 1.
Discussion
The study aimed to discover the influence of brain- derived
neurotrophic factor (BDNF) single nucleotide polymorph-
ism (SNP) Val66Met on olfactory function. Brain- derived
neurotrophic factor (BDNF) is widely expressed in the
adult hippocampus and neocortex [29]. It is considered an
important neurotrophic factor for neuronal differentiation
and life-long plasticity and repair [30]. BDNF Val66Met
polymorphism impairs activity-dependent BDNF excretion
and has been associated with changes in cortical and sub-
cortical anatomy [31,32]. BDNF Val66Met polymorphism
is strictly related to cognitive function. In particular, Met
carriers show impaired ability in declarative memory tasks,
as well as a decrease in engagement of particular areas,
such as the hippocampus, during encoding and retrieval
[33], although current findings are still contradictory
[34,35], and a recent meta-analysis reported no significant
correlation between Val66Met SNP and the cognitive phe-
notypes [36]. BDNF also appears to influence the olfactory
function, since the modulation of proliferation and survival
of olfactory receptors is one of its key-roles, according to
Simpson et al. [20]. The expression of BDNF Val66Met
SNP is relevant in particular areas, involved in olfactory
processing and part of the olfactory pathway, such as in
the olfactory bulb, whose neurogenesis disruption is strictly
related to the BDNF Val66Met variant. To date, only one
work has been published showing an association between
olfactory function (identification task) and BDNF
Val66Met SNP in humans [24], but the effect of this SNP
in young adults was not investigated, nor was its effect on
other important tasks, such as olfactory discrimination.
Furthermore, we chose to employ the complete Sniffin’Sticks Extended Test in order to evaluate eventual varia-
tions occurring at different levels of the olfactory pathway.
In particular, a clear impairment for Met carriers was
found in all tasks, suggesting the profound influence of this
genetic variant on the good functioning of the olfactory
pathway. Several key limitations need to be acknowledged.
First, although the present study seems to be sufficiently
powered, our sample size is relatively small, thus making
statistical estimations less robust. Second, the frequencies
of the Val and Met alleles of BDNF Val66Met vary by eth-
nicity; about 80% of the European population, but only
50% of the Asian population, carry it [16]. Another limita-
tion of our study is the lack of a more comprehensive gen-
etic analysis of polymorphisms potentially associated with
olfactory function [37].
Conclusions
Despite these limitations, we were able to show a relevant
influence of BDNF Val66Met polymorphism on olfactory
function. These findings could have implications for the
evaluation of olfactory function and for relating its impair-
ment to cognitive decline and neurodegenerative diseases.
Further investigation are needed to substantiate this rela-
tionship in larger subgroups of populations of different
ethnic backgrounds.
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